Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Xavier Castellsagué, Kevin A. Ault, F. Xavier Bosch, Darron Brown, Jack Cuzick, Daron G. Ferris, Elmar A. Joura, Suzanne M. Garland, Anna R. Giuliano, Mauricio Hernandez-Avila, Warner Huh, Ole Erik Iversen, Susanne K. Kjaer, Joaquin Luna, Joseph Monsonego, Nubia Muñoz, Evan Myers, Jorma Paavonen, Punnee Pitisuttihum, Marc StebenCosette M. Wheeler, Gonzalo Perez, Alfred Saah, Alain Luxembourg, Heather L. Sings, Christine Velicer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalPapillomavirus Research
Volume2
DOIs
StatePublished - Dec 1 2016

Fingerprint

Latin America
Genotype
Vaccines
North America
Neoplasms
Northern Asia
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Sample Size
Placebos
Clinical Trials
Pathology
Infection

Keywords

  • Adenocarcinoma in situ
  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • Human papillomavirus

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. / Castellsagué, Xavier; Ault, Kevin A.; Bosch, F. Xavier; Brown, Darron; Cuzick, Jack; Ferris, Daron G.; Joura, Elmar A.; Garland, Suzanne M.; Giuliano, Anna R.; Hernandez-Avila, Mauricio; Huh, Warner; Iversen, Ole Erik; Kjaer, Susanne K.; Luna, Joaquin; Monsonego, Joseph; Muñoz, Nubia; Myers, Evan; Paavonen, Jorma; Pitisuttihum, Punnee; Steben, Marc; Wheeler, Cosette M.; Perez, Gonzalo; Saah, Alfred; Luxembourg, Alain; Sings, Heather L.; Velicer, Christine.

In: Papillomavirus Research, Vol. 2, 01.12.2016, p. 61-69.

Research output: Contribution to journalArticle

Castellsagué, X, Ault, KA, Bosch, FX, Brown, D, Cuzick, J, Ferris, DG, Joura, EA, Garland, SM, Giuliano, AR, Hernandez-Avila, M, Huh, W, Iversen, OE, Kjaer, SK, Luna, J, Monsonego, J, Muñoz, N, Myers, E, Paavonen, J, Pitisuttihum, P, Steben, M, Wheeler, CM, Perez, G, Saah, A, Luxembourg, A, Sings, HL & Velicer, C 2016, 'Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region', Papillomavirus Research, vol. 2, pp. 61-69. https://doi.org/10.1016/j.pvr.2016.03.002
Castellsagué, Xavier ; Ault, Kevin A. ; Bosch, F. Xavier ; Brown, Darron ; Cuzick, Jack ; Ferris, Daron G. ; Joura, Elmar A. ; Garland, Suzanne M. ; Giuliano, Anna R. ; Hernandez-Avila, Mauricio ; Huh, Warner ; Iversen, Ole Erik ; Kjaer, Susanne K. ; Luna, Joaquin ; Monsonego, Joseph ; Muñoz, Nubia ; Myers, Evan ; Paavonen, Jorma ; Pitisuttihum, Punnee ; Steben, Marc ; Wheeler, Cosette M. ; Perez, Gonzalo ; Saah, Alfred ; Luxembourg, Alain ; Sings, Heather L. ; Velicer, Christine. / Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. In: Papillomavirus Research. 2016 ; Vol. 2. pp. 61-69.
@article{f00920809bd84cfd81f39b2130d7c55b,
title = "Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region",
abstract = "Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50{\%}) and CIN2/3 (81-85{\%}). Types 31/33/45/52/58 accounted for 25-30{\%} of CIN1 in Latin America and Europe, but 14-18{\%} in North America and Asia. Types 31/33/45/52/58 accounted for 33-38{\%} of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18{\%} of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11{\%} of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.",
keywords = "Adenocarcinoma in situ, Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus",
author = "Xavier Castellsagu{\'e} and Ault, {Kevin A.} and Bosch, {F. Xavier} and Darron Brown and Jack Cuzick and Ferris, {Daron G.} and Joura, {Elmar A.} and Garland, {Suzanne M.} and Giuliano, {Anna R.} and Mauricio Hernandez-Avila and Warner Huh and Iversen, {Ole Erik} and Kjaer, {Susanne K.} and Joaquin Luna and Joseph Monsonego and Nubia Mu{\~n}oz and Evan Myers and Jorma Paavonen and Punnee Pitisuttihum and Marc Steben and Wheeler, {Cosette M.} and Gonzalo Perez and Alfred Saah and Alain Luxembourg and Sings, {Heather L.} and Christine Velicer",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.pvr.2016.03.002",
language = "English (US)",
volume = "2",
pages = "61--69",
journal = "Papillomavirus Research",
issn = "2405-8521",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

AU - Castellsagué, Xavier

AU - Ault, Kevin A.

AU - Bosch, F. Xavier

AU - Brown, Darron

AU - Cuzick, Jack

AU - Ferris, Daron G.

AU - Joura, Elmar A.

AU - Garland, Suzanne M.

AU - Giuliano, Anna R.

AU - Hernandez-Avila, Mauricio

AU - Huh, Warner

AU - Iversen, Ole Erik

AU - Kjaer, Susanne K.

AU - Luna, Joaquin

AU - Monsonego, Joseph

AU - Muñoz, Nubia

AU - Myers, Evan

AU - Paavonen, Jorma

AU - Pitisuttihum, Punnee

AU - Steben, Marc

AU - Wheeler, Cosette M.

AU - Perez, Gonzalo

AU - Saah, Alfred

AU - Luxembourg, Alain

AU - Sings, Heather L.

AU - Velicer, Christine

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

AB - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

KW - Adenocarcinoma in situ

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - Human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=84961675401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961675401&partnerID=8YFLogxK

U2 - 10.1016/j.pvr.2016.03.002

DO - 10.1016/j.pvr.2016.03.002

M3 - Article

C2 - 29074187

AN - SCOPUS:84961675401

VL - 2

SP - 61

EP - 69

JO - Papillomavirus Research

JF - Papillomavirus Research

SN - 2405-8521

ER -